Skip to main content

Methadone Tied to Lower Risk for Discontinuation Versus Buprenorphine/Naloxone

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 18, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, Oct. 18, 2024 -- Receipt of methadone for opioid use disorder is associated with a lower risk for treatment discontinuation compared with buprenorphine/naloxone, according to a study published online Oct. 17 in the Journal of the American Medical Association.

Bohdan Nosyk, Ph.D., from Simon Fraser University in Burnaby, British Columbia, Canada, and colleagues assessed the risk for treatment discontinuation and mortality among individuals receiving buprenorphine/naloxone versus methadone for the treatment of opioid use disorder. The analysis included 30,891 incident adult users (2010 to 2020) who were not incarcerated, pregnant, or receiving palliative cancer care.

The researchers found that incident users of buprenorphine/naloxone had a higher risk for treatment discontinuation versus methadone in initiator analyses (88.8 versus 81.5 percent discontinued at 24 months; adjusted hazard ratio [HR], 1.58). Similar results were found when evaluated at optimal dose in a per-protocol analysis (42.1 versus 30.7 percent; adjusted HR, 1.67). Mortality while receiving treatment showed ambiguous results in per-protocol analyses (incident users: 0.08 versus 0.13 percent mortality at 24 months; adjusted HR, 0.57; 95 percent confidence interval [CI], 0.24 to 1.35; prevalent users: 0.08 versus 0.09 percent; adjusted HR, 0.97; 95 percent CI, 0.54 to 1.73). Similar results were seen after the introduction of fentanyl and across patient subgroups.

“As the use of more potent synthetic opioids continues to increase in North America and elsewhere, clinical guidelines for all aspects of the treatment of people with opioid use disorders require reconsideration to reduce the risk of discontinuation of treatment,” the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted October 2024

Read this next

Hospital Addiction Consultation Service Aids Opioid Use Disorder

WEDNESDAY, April 16, 2025 -- A hospital-based addiction consultation service can improve receipt of evidence-based treatment for people with opioid use disorder (OUD), according...

Lower Oral Health Scores Linked to Higher Pain Scores in Women

MONDAY, April 14, 2025 -- Low oral health scores are associated with higher pain scores, including migraine headache, among women, according to a study published online April 9 in...

ACP: Guidance Provided for Use of Cannabis in Chronic Noncancer Pain Management

MONDAY, April 7, 2025 -- In a best practice guideline issued by the American College of Physicians and published online April 4 in the Annals of Internal Medicine, advice is...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.